Antidiabetic activity of the chemical constituents of Combretum dolichopetalum root in mice by Uzor, Philip F. & Osadebe, Patience O.
EXCLI Journal 2016;15:290-296 – ISSN 1611-2156 
Received: March 12, 2016, accepted: April 19, 2016, published: April 25, 2016 
 
 
290 
Original article: 
ANTIDIABETIC ACTIVITY OF THE CHEMICAL CONSTITUENTS OF 
COMBRETUM DOLICHOPETALUM ROOT IN MICE 
 
Philip F. Uzor*, Patience O. Osadebe 
 
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, 
University of Nigeria, Nsukka, 410001, Enugu State, Nigeria 
 
* Corresponding author: E-mail: philip.uzor@unn.edu.ng; Tel: +234-8037008294  
 
http://dx.doi.org/10.17179/excli2016-252  
 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0/). 
 
 
 
ABSTRACT 
The root of Combretum dolichopetalum (Combreatacea) is used in ethnomedicine for the management of diabe-
tes mellitus. Though some compounds have been isolated from it, the antidiabetic principles have not been iden-
tified. The present study was designed to evaluate the chemical constituents from the root of C. dolichopetalum 
with a view to identifying the antidiabetic principles. The constituents include the alkaloids, echinulin (1) and 
arestrictin B (2), the terpenoids, arjunolic acid (3) and 4'-dihydrophaseic acid (4) as well as the phenolic acids, 
ellagic acid (5) and 3, 4, 3'-tri-O-methylellagic acid (6). Twenty eight mice (in seven groups, n = 4) were made 
diabetic using alloxan monohydrate (i.p., 120 mg/kg) and treated orally with either the vehicle (control group), 
any of the constituents or glibenclamide (standard drug). The fasting blood glucose of the diabetic animals was 
monitored for nine hours. Results showed that all the chemical constituents (1-6) exhibited significant (p < 0.05) 
antidiabetic activity comparable to glibenclamide. The alkaloids exhibited the most profound antidiabetic activi-
ty. The present study has thus identified the antidiabetic principles of C. dolichopetalum root as echinulin, are-
strictin B, arjunolic acid, 4'-dihydrophaseic acid, ellagic acid and 3, 4, 3'-tri-O-methylellagic acid. The study has 
further validated the ethnomedicinal use of the root of C. dolichopetalum in diabetes.  
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INTRODUCTION 
Diabetes mellitus is a chronic metabolic 
disorder which is characterized by hypergly-
cemia and long term complications such as 
retinopathy, nephropathy, neuropathy, and 
angiopathy. Diabetes remains one of the 
leading causes of death worldwide. The 2015 
estimate by the International Diabetes Feder-
ation (IDF) shows that 1 in 11 adults have 
diabetes (415 million) and the figure is pro-
jected to rise to1 adult in 10 (642 million) in 
2040. The estimate also shows that diabetes 
caused 5.0 million deaths implying that eve-
ry six seconds a person dies from diabetes. 
This metabolic disorder caused at least USD 
673 billion, representing 12 % of global 
health expenditure (IDF, 2015). The increas-
ing worldwide incidence of diabetes consti-
tutes a significant impact on the health, qual-
ity of life, and life expectancy of patients, as 
well as on the global public health care sys-
tem.  
In conventional practice, management of 
type 1 diabetes is by exogenous insulin while 
type 2 is by oral agents including the sul-
fonylureas, biguanides, α-glucosidase inhibi-
tors, glitazones, gliptins, and the SGLT 2 in-
hibitors, which are used as monotherapy or 
in combination to achieve better glycemic 
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regulation since they have different modes of 
action. Despite the existing pharmacothera-
py, it is still difficult to attain adequate gly-
cemic control amongst many diabetic pa-
tients due to the progressive decline in β-cell 
function (Wallace and Matthews, 2000). 
Moreover, many of these oral antidiabetic 
agents have a number of serious adverse ef-
fects (Pepato et al., 2005). The low efficacy 
and the adverse effects of some of the con-
ventional antidiabetic agents together with 
the increasing global incidence of diabetes 
necessitate the urgent search for more potent 
and safer alternatives from natural sources 
such as medicinal plants.  
As part of our on-going search for antidi-
abetic agents from natural sources (Osadebe 
et al., 2014; Uzor et al., 2014), we have fur-
thered our investigation on the root of Com-
bretum dolichopetalum (Combretaceae) 
Engl. and Diels. The plant is a scandent 
shrub or forest liana. The root extract is used 
in traditional medicine for dysentery, indi-
gestion and in the management of diabetes 
(Uzor et al., 2014). The antisecretory (Asuzu 
and Onu, 1990), anti-hepatotoxic (Udem et 
al., 1997) and trypanocidal (Udem et al., 
1996) activities of this plant have been re-
ported. We have recently investigated the an-
tidiabetic activity of the root extract and frac-
tions of this plant on diabetic animals and es-
tablished that the antidiabetic fractions con-
tain steroids, terpenes, alkaloids and flavo-
noids (Uzor et al., 2014). Additionally, our 
more recent chemical investigation led to the 
isolation of six known metabolites (Figure 1) 
from the root of the plant, including the alka-
loids echinulin (1) and arestrictin B (2), ter-
penoids, arjunolic acid (3) and 4'-dihydro-
phaseic acid (4), as well as phenolic acids el-
lagic acid (5) and 3, 4, 3'-tri-O-methylellagic 
acid (6) (Uzor et al., 2015). These com-
pounds were investigated for their cytotoxic 
potentials using the L5178Ymouse lympho-
ma cell lines but their antidiabetic potentials 
have not been assessed. Thus the antidiabetic 
constituents of the root of this plant have not 
been identified. The current study was there-
fore designed to evaluate the antidiabetic ac-
tivity of the isolated constituents from the 
root of this plant. To the best of our 
knowledge, this is the first report of antidia-
betic compounds from C. dolichopetalum 
root. 
 
 
 
1 
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Figure 1: Isolated compounds from C. dolichopetalum root  
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EXPERIMENTAL 
Chemicals 
Alloxan monohydrate was purchased 
from Sigma-Aldrich while glibenclamide 
was purchased from NGC. All other chemi-
cals were of analytical grade. 
 
Plant material 
Roots of Combretum dolichopetalum 
were collected in Nsukka, Nigeria, in April 
2014 and identified by Mr. A. Ozioko, a tax-
onomist with the International Center for 
Ethnomedicine and Drug Development (In-
terCEDD), Nsukka. A voucher specimen (In-
terCEDD/853) is deposited at the Herbarium 
of the Department of Pharmaceutical and 
Medicinal Chemistry, University of Nigeria, 
Nsukka.  
 
Extraction and isolation  
The procedures for the isolation of the 
constituents of C. dolichopetalum root to ob-
tain 1-6 have been recently described (Uzor 
et al., 2015). Compounds 1 and 2 (or 1/2), 
two isomeric indole-containing diketopiper-
azine alkaloids, were obtained as a mixture 
(56:54). They were thus evaluated as one 
sample.  
 
Animals 
Swiss albino mice (18.0–24.2 g) of either 
sex were used for the studies. The animals 
were kept in standard polypropylene cages at 
room temperature and 60-65 % relative hu-
midity during the experimental work with 
12 h day: 12 h night cycle. They were fed 
with normal laboratory diet and allowed to 
drink water ad libitum. The experimental 
protocols followed the guidelines of the Eth-
ics Committee of the University of Nigeria 
and the European Community guidelines 
(EEC Directive of 1986; 86/609/EEC) (EEC, 
1986). 
 
Antidiabetic study  
Twenty eight (28) albino mice were 
fasted for 12 h prior to induction of hyper-
glycemia. Diabetes was induced using 
freshly prepared solution of alloxan mono-
hydrate (i.p. at 120 mg/kg body weight) as 
previously reported (Uzor et al., 2014). After 
the induction, the diabetic animals were ran-
domly divided into seven groups (n = 4) and 
treated orally according to the following pro-
tocols:  
Group A: alloxan + 2 mL/kg of vehicle 
Group B: alloxan +20 mg/kg of 1/2 
Group C: alloxan + 20 mg/kg of 3 
Group D: alloxan + 10 mg/kg of 4 
Group E: alloxan + 20 mg/kg of 5 
Group F: alloxan + 20 mg/kg of 6 
Group G: alloxan + 0.2 mg/kg of  
glibenclamide  
Blood sample was withdrawn from the 
tail vein and fasting blood glucose (FBG) 
was measured with a glucometer (Accu-
chek®, Roche) at 0, 1, 3, 6 and 9 h. Mice 
model was used since the compounds were 
limited in quantity.  
 
Statistical analysis 
The data obtained were analyzed using a 
statistical software (SPSS version 21) and re-
sults expressed as mean ± SEM. The means 
were subjected to one way analysis of va-
riance (ANOVA) for determining the signi-
ficant difference. The significance between 
the various groups and the control was ana-
lyzed further by post hoc Dunnet’s test (2-
sided). Group mean was considered to be si-
gnificantly different from that of the control 
group at p < 0.05. 
 
RESULTS 
The results of the antidiabetic activities 
of the isolated chemical constituents are 
shown in Table 1. All the constituents (1-6) 
exhibited significant (p < 0.05) reduction of 
the FBG of the diabetic mice after 3 h but the 
effect of the alkaloids, (1/2), was most pro-
nounced and sustained. The antidiabetic ef-
fect of the alkaloids was maximal at 3 h after 
administration (53.40 % reduction of FBG). 
Among the constituents, 1/2 was followed in 
antidiabetic potency by 5 (23.7 % maximal 
reduction in 9 h), 6 (22.7 % reduction in 
3 h), 4 (17.91 % maximal reduction of FBG 
in 6 h), and then by 3 (17.27 % reduction in 
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Table 1: Effect of the chemical constituents from C. dolichopetalum root on the FBG of 
alloxan-induced diabetic mice 
Group Treatment 
FBG (mg/dL) 
Basal 
Time (h) 
0 1 3 6 9 
A Control (vehicle) 77.00 ± 3.89 
221.25 
± 17.93 
246.25 
± 20.78 
350.50 
± 15.71 
256.25 
± 42.53 
278.50 
± 27.39 
B 1/2 (20 mg/kg) 63.50* ± 1.85 
249.00 
± 39.01 
218.00 
± 25.54 
(12.45 %) 
116.00*** 
± 4.60 
(53.40 %) 
158.00 
± 46.70 
(36.55 %) 
238.75 
± 43.11 
(4.12 %) 
C 3 (20 mg/kg) 66.25 ± 3.22 
250.50 
± 35.44 
256.25 
± 21.68 
(-2.20 %) 
207.25*** 
± 19.95 
(17.27 %) 
224.75 
± 27.79 
(10.40 %) 
238.75 
± 33.46 
(-11.18 %)
D 4 (10 mg/kg) 63.50* ± 2.06 
353.25** 
± 17.14 
339.00** 
± 12.50 
(4.03 %) 
302.75* 
± 2.43 
(14.30 %) 
290.00 
± 4.08 
(17.91 %) 
296.00 
± 4.85 
(16.21 %) 
E 5 (20 mg/kg) 62.00* ± 2.16 
267.50 
± 18.39 
278.75 
± 12.16 
(-4.20 %) 
220.75*** 
± 13.62 
(17.48 %) 
224.00 
± 17.33 
(16.26 %) 
204.50 
± 27.29 
(23.55 %) 
F 6 (20 mg/kg) 66.50 ± 3.11 
210.25 
± 18.87 
226.25 
± 11.81 
(7.61 %) 
162.50*** 
± 8.93 
(22.71 %) 
259.75 
± 35.51 
(-23.54 %) 
218.50 
± 28.71 
(-3.90 %) 
G Glibenclamide (0.2 mg/kg) 
56.25*** 
± 2.59 
253.00 
± 10.07 
156.25** 
± 10.14 
(38.24 %) 
146.50*** 
± 5.91 
(42.10 %) 
144.50** 
± 6.65 
(42.89 %) 
129.75*** 
± 1.31 
(48.72 %) 
Results are expressed as mean ± SEM (n = 4). *p < 0.05, ** p < 0.01, *** p < 0.001, as compared with Control group (one way 
ANOVA followed by Dunnet’s t-test). Values in parenthesis denote percentage reduction of blood glucose from 0 h. 
 
3 h). Even at 10 mg/kg, 4 exhibited signifi-
cant antidiabetic activity by lowering the 
FBG (17.91 %) of the diabetic mice. Overall, 
the effect of the compounds was comparable 
to that of glibenclamide (reduction of 
48.72 % in 9 h). 
 
DISCUSSION 
The present study has shown that the 
compounds from the root of C. dolichop-
etalum possess antidiabetic activity. The pre-
sent observation validates the traditional use 
of the plant in diabetes. Other plant species 
from Combretaceae have been known to 
contain diverse chemical constituents such as 
ellagic acid, gallic acid, ellagitannins and 
gallotannins; they have been also known for 
a long time to show pharmacological effects 
like antioxidant, antibacterial and antidiabet-
ic activities (Sabu and Kuttan, 2002). Previ-
ous report shows that echinuline (1) exhibits 
moderate protein tyrosine phosphatase 1B 
(PTP1B) inhibitory activity (Sohn et al., 
2013) which suggests the possible antidia-
betic activity of 1. The biological activity of 
arestrictin B (2) was not evaluated in a study 
where it was first isolated in a pure form 
from xerophilic fungi (Itabashi et al., 2006). 
Thus it is possible that one or both of the two 
isomeric alkaloids possess antidiabetic activ-
ity or they could be acting synergistically. 
Further studies on the separation of the alka-
loids and evaluation of their individual anti-
diabetic activities are envisaged. These two 
compounds have been isolated singly espe-
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cially from fungal sources but they were re-
ported, for the first time, as having occurred 
together in C. dolichopetalum root (Uzor et 
al., 2015). 
Similar to the alkaloids above, our find-
ings showed that arjunolic acid (3) was one 
of the antidiabetic constituents of C. doli-
chopetalum. The triterpenoid, 3, is also pos-
sibly acting synergistically with other bioac-
tive constituents. Previous reports support 
our present observation. Compound 3 was 
isolated from Lagerstroemia speciosa leaves 
and tested for its alpha glucosidase activity 
using yeast alpha glucosidase enzyme. It was 
shown that 3 inhibited the enzyme with IC50 
of 18.63 ± 0.32 µg/mL while the standard 
drugs, acarbose and voglibose, showed no 
inhibition (Hou et al., 2009). Other studies 
have also supported the beneficial role of 3 
in diabetes (Ghosh and Sil, 2013; Manna et 
al., 2009a, b; Manna and Sil, 2012).  
The results of the present study have 
shown that dihydrophaseic acid (4), a deriva-
tive of S(+)-abscisic acid (ABA) (Hirai et 
al., 2003) exhibits significant (p < 0.05) anti-
diabetic property. ABA, a plant hormone, 
has been shown to exhibit antidiabetic effect 
through peroxisome proliferator-activated 
receptor gamma (PPAR γ) activation (Guri et 
al., 2010). It is therefore possible that 4 ex-
hibits its antidiabetic activity through PPAR 
γ activation similar to its precursor, ABA. 
The present study is probably the first report 
of the antidiabetic activity of this ABA me-
tabolite. However, one study shows that 4 
exhibited some biological activities such as 
cytotoxicity, lipid peroxidation inhibition ef-
fect, mild hydroxyl radical scavenging ac-
tivity, and DNA protective effect (Lin et al., 
2014).  
We have also observed that ellagic acid 
(5) was one of the bioactive antidiabetic 
principles of C. dolichopetalum root. Previ-
ous study has demonstrated the antidiabetic 
activity of 5 in vivo (Malini et al., 2011). 
Moreover, 5 has been widely reported as an 
inhibitor of aldose reductase enzyme and in-
hibitor of the formation of advanced gly-
cation end products (Kim et al., 2008). Al-
dose reductase inhibitors are an attractive 
pharmacological target for the treatment of 
diabetic complications. Compound 6, which 
is a methylated derivative of 5 also showed 
in vivo antidiabetic activity in the present 
study. Earlier studies showed the α-
glucosidase inhibitory effect of the methylat-
ed derivatives of 5 (Tabopda et al., 2008). 
Furthermore, methylated derivatives of 5 are 
known to play some roles in antidiabetic ac-
tivities of plants. While 6 showed glucose 
transport stimulatory activity, 5 did not show 
such activity (Bai et al., 2008). This suggests 
that methylation of the OH group of 5 is 
necessary for antidiabetic activity.  
 
CONCLUSION 
The present study has shown that all the 
isolated constituents of C. dolichopetalum 
root including the alkaloids (echinulin and 
arestrictin B), arjunolic acid, 4'-dihydro-
phaseic acid, ellagic acid and as 3, 4, 3'-tri-
O-methylellagic acid were identified as the 
major antidiabetic active principles of the 
plant. It is possible that these metabolites ex-
ert synergistic effect in their antidiabetic ac-
tivities. The study has further validated the 
ethnomedicinal use of the root of C. doli-
chopetalum in the management of diabetes.  
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